Clinical Trials List
2024-03-01 - 2031-12-31
Phase I/II
Not yet recruiting3
Recruiting1
ICD-10C61
Malignant neoplasm of prostate
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9185
Malignant neoplasm of prostate
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- 沈鼎文 無
- 張境夫 無
- 黃亮鋼 無
- 余紹銘 無
- PO-HUNG LIN 無
- See-Tong Pang 無
- Feng-Yuan Liu 無
- 吳俊德 無
- I-hung Shao 無
- 黃文冠 無
- Hong-Cheng Gan 無
- Yung-Chang Lin 無
- Yung-Chia Kao 無
- Kai-Jie Yu 無
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Jia-An Hong 無
- 彭昱璟 無
- 蔡承翰 無
- Tzu-Ping Lin 無
- Tzu-Hsiang Hsu 無
- William Huang 無
- Tzu-chun Wei 無
- Chih-Chieh Lin 無
- 陳威任 無
- Liang-Yu Lin 無
- Chien-Hsin Ting 無
- Yen-Hwa Chang 無
- Tzu-Hao Huang 無
- Hsiao-Jen Chung 無
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Chi-Ping Huang 無
- Chao-Hsiang Chang 無
- Po-Fan Hsieh 無
- Han Chang 無
- 謝德鈞 無
- Wei-Ching Lin 無
- Chi-Rei Yang 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
14 participants
-
Global
220 participants
